HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind comparison of zimelidine and amitriptyline in depressive out-patients.

Abstract
A double-blind, randomized clinical study was conducted in thirty-four out-patients suffering from major depressive disorders comparing zimelidine with amitriptyline. The dosage was flexible, maintenance doses varying between 50-150 mg in the amitriptyline group and 50-300 mg in the zimelidine group. After a wash-out period of at least a week the mean score in Hamilton Rating Scale for depression (HRS) was 22.2 for zimelidine and 21.9 for amitriptyline. During the treatment period of 6 weeks, zimelidine and amitriptyline appeared to be equally effective as antidepressants in HRS and Global Ratings. The zimelidine group showed significantly less somnolence and dry mouth. No clinically important changes were seen in the laboratory parameters during the study.
AuthorsE Syvälahti, J Salminen, V Lehtinen
JournalThe Journal of international medical research (J Int Med Res) Vol. 10 Issue 4 Pg. 250-6 ( 1982) ISSN: 0300-0605 [Print] England
PMID6214441 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antidepressive Agents
  • Pyridines
  • Amitriptyline
  • Zimeldine
  • Brompheniramine
Topics
  • Adult
  • Ambulatory Care
  • Amitriptyline (adverse effects, therapeutic use)
  • Antidepressive Agents (therapeutic use)
  • Brompheniramine (adverse effects, analogs & derivatives, therapeutic use)
  • Clinical Trials as Topic
  • Depressive Disorder (drug therapy, psychology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Pyridines (therapeutic use)
  • Zimeldine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: